Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

CDKN2A

12 articles · Resources: NCBI Gene, OncoKB

Clinical · Bioinfo & AI

Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

Skoulidis F, Jabbour SK, Garon EB, et al.

Clinical cancer research

The TRIDENT study is a post-hoc analysis of the phase III POSEIDON trial, which evaluated the addition of tremelimumab to durvalumab and chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). This analysis utilized machine learning models integrating clinical, genomic, and radiomic data to identify patients who would derive greater overall survival (OS) benefit from the addition of tremelimumab. Results showed that the top-ranked 50% of patients with nonsquamous tumors, as identified by the model, achieved a hazard ratio of 0.56 for OS. Factors such as KRAS and STK11 mutations, along with wild-type EGFR, FGFR3, and CDKN2A, were strongly associated with higher OS benefit.

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical · Molecular biology · Bioinfo & AI

Pleomorphic Liposarcoma: Comprehensive Genomic Analysis of 39 Cases With Comparison to Other Genomically Complex Sarcomas

Yakoub MA, Saoud C, Kim D, et al.

Genes, chromosomes & cancer

This study conducted comprehensive genomic profiling on 39 cases of pleomorphic liposarcoma (PLPS) to characterize its molecular landscape and compare it with other complex sarcomas like UPS and MFS. Analyses revealed that TP53 (87%) and RB1 (51%) alterations are the most frequent in PLPS, and significantly more common than in UPS and MFS. MYC amplification was associated with significantly shorter overall survival, suggesting a prognostic role. Furthermore, correlations were established between gene alterations and morphological features, including CYSLTR2 alterations in cases with predominant pleomorphic lipoblasts. These findings highlight the molecular distinctiveness of PLPS and provide insights for future diagnostic and therapeutic strategies.

Clinical · Molecular biology

Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine

Crane K, Bhat KRS, Grivas P, et al.

Oncotarget

This study characterized the prevalence of KRAS G12C mutations in genitourinary malignancies, an area with limited data despite the approval of targeted therapies. Comprehensive genomic profiling was performed on over 13,000 samples of renal clear cell carcinomas, urothelial bladder carcinomas, and prostate acinar adenocarcinomas. Results indicated that KRAS G12C mutations are infrequent in these tumors, with an incidence of 0% in renal carcinomas, 0.6% in urothelial bladder carcinomas, and less than 0.01% in prostate adenocarcinomas. Despite their low frequency, these mutations represent an emerging therapeutic target, warranting further investigation, particularly in basket trials for patients harboring this actionable alteration.

Clinical

Early-Stage Oral Squamous Cell Carcinoma in Adolescents and Young Adults Compared with Older Patients Exhibits Distinct Clinicopathological Features

Ono S, Hirose K, Kawai H, et al.

Head and neck pathology

This retrospective study compared the clinicopathological features of stage I-II oral squamous cell carcinoma (OSCC) in adolescents and young adults (AYAs) versus older patients. OSCCs in AYAs are more frequently located on the tongue and exhibit distinct histological patterns, including an abnormal TP53 immunophenotype. Although AYAs demonstrate significantly better overall and disease-free survival, a depth of invasion (DOI) greater than 5 mm is a major prognostic indicator for distant metastasis and poorer survival within this group. Other factors such as clinical stage, tumor thickness, and tumor budding may also predict the risk of postoperative lymph node metastasis. Tested molecular markers did not provide robust prognostic stratification.

Clinical · Molecular biology · Bioinfo & AI

Segmental Copy Number Variant Detection Using an Amplicon-Based Next-Generation Sequencing Panel for Integrated Glioma Classification

Sarvananthan K, Santos S, Saylor B, et al.

The Journal of molecular diagnostics

This study describes a custom analysis method for detecting segmental copy number variants (CNVs) using an amplicon-based NGS panel (Oncomine Comprehensive Assay v3) for integrated glioma classification. The developed algorithm identifies critical biomarkers such as 1p/19q codeletion, +7/-10, EGFR amplification, and CDKN2A/B homozygous deletion. Validated across three cohorts, the approach demonstrated 100% concordance with FISH for all biomarkers in the validation cohort. Its clinical implementation significantly reduced required FISH studies by 90%, thereby shortening turnaround times and decreasing molecular testing costs.

Clinical · Molecular biology

Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

Dymun A, Jeng MY, Elkrief A, et al.

Science translational medicine

This study investigates histologic transformation to lung squamous cell carcinoma (LUSC) in EGFR-mutant lung adenocarcinoma (LUAD) patients, an underrecognized resistance mechanism. Multiomic analyses revealed that patients with transforming or adenosquamous (LUAS) phenotypes experienced shorter overall survival on first-line osimertinib. Inactivation of the retinoblastoma (Rb) pathway, particularly via CDKN2A/B deletions, was identified as a key driver of this transformation. Furthermore, MET pathway upregulation was observed, and combined EGFR and MET inhibition demonstrated efficacy in preclinical models. These findings suggest novel strategies to counteract this aggressive form of resistance.

Clinical · Molecular biology

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib

Piotrowska Z, Ahn MJ, Voon PJ, et al.

Cancer discovery

The prospective, multicenter ELIOS study characterized acquired resistance mechanisms to first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). By analyzing paired tumor biopsies taken pre-treatment and post-progression, the study identified frequent alterations including MET amplification, CDKN2A/CDKN2B and MTAP deletions, and the EGFR C797S mutation. Proteogenomic analysis also revealed high TROP2 expression, irrespective of genetic alterations. The findings highlight the heterogeneous nature of resistance and the complementary utility of tissue and liquid biopsies for alteration detection. This study emphasizes the need for therapeutic strategies targeting multiple resistance pathways.

Clinical · Molecular biology

Genetic mutations in metastatic adenocarcinoma of unknown primary

Nagano H, Kiyama S, Kyutoku T, et al.

Otolaryngologia polska = The Polish otolaryngology

This study analyzed the genomic profile of 480 patients with metastatic adenocarcinoma of unknown primary (ACUP) using the FoundationOne CDx platform. The most frequent mutations included TP53, KRAS, and CDKN2A. Results showed that GNAS and PIK3CA mutations were associated with better overall survival. Conversely, ARID1A and NOTCH1 alterations were linked to a worse prognosis. These findings highlight the significance of specific genomic alterations as prognostic markers in ACUP.

Clinical · Molecular biology

Circulating Tumor High Risk HPV DNA as the HPV-Specific Test in Oropharyngeal Squamous Cell Carcinoma Patients

Hidalgo CM, Yin LX, Bogan AW, et al.

Head and neck pathology

This study investigated the concordance of circulating tumor human papillomavirus DNA (ctHPVDNA) with tissue-based HPV testing for diagnosing HPV-associated oropharyngeal squamous cell carcinoma (HPV+OPSCC). Researchers analyzed 236 patients, comparing ctHPVDNA (NavDx assay) results with p16 immunohistochemistry and ISH. ctHPVDNA demonstrated 100% specificity and positive predictive value, suggesting a positive result is highly reliable. However, its sensitivity of 85% and negative predictive value of 17% indicate that a negative result still necessitates confirmation with tissue-based tests.

Clinical · Molecular biology

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies

Aldea M, Lenahan SM, Locquet MA, et al.

Annals of oncology

Homozygous MTAP loss is frequently observed in oncogene-driven non-small-cell lung cancers (NSCLC), particularly in EGFR, ALK, and RET altered subtypes. While this loss did not significantly impact the response to first-line targeted therapies, it creates a selective vulnerability to PRMT5 inhibitors. Preclinical studies demonstrated that the PRMT5 inhibitor BMS-986504 is active in MTAP-deleted NSCLC models and can enhance the efficacy of existing targeted therapies. These findings suggest a novel combined therapeutic strategy for NSCLC patients with MTAP loss.

Clinical · Molecular biology

The impact of next generation sequencing studies on the diagnosis of BAP1 inactivated melanocytic tumors

Braat J, Trichy NS, Holic LJ, et al.

Human pathology

This study investigates the impact of next-generation sequencing (NGS) on the diagnosis of BAP1 inactivated melanocytic tumors (BIMTs), which often exhibit significant morphological atypia, complicating their classification. A survey among dermatopathologists revealed that incorporating NGS results significantly improved diagnostic accuracy and interobserver agreement. Specific genomic aberrations, including pathogenic variants in TERT-p, CDKN2A, PTEN, and MYC amplification, were found exclusively in malignant cases. These findings suggest that NGS could refine melanoma diagnosis, which is critical for guiding access to effective therapies.